In May 2022, MESOX participated in the activities of the LSX World Congress in London. The meeting brought together executives and leaders from Biotech, Healthtech and Medtech companies to discuss the latest developments in life sciences and partnership opportunities.
At the event, our team had the opportunity to showcase our pioneering carrier technology to potential partners from pharmaceutical and biotech companies.
MESOX has just won the National Start-Up Award from Medilink UK, building upon the earlier regional win in the Midlands from Medilink Midlands in May this year. The judges highlighted two compelling reasons for their choice: MESOX’s work to develop advanced carrier technology with a mission to transform the development of pharmaceuticals, enhance bioavailability, and
MESOX and EuroAPI, a leading CDMO, are partnering to accelerate the development and manufacture of innovative drug delivery carriers. Our collaboration focuses on scaling up MESOX’s pioneering nanopore carrier technology, leveraging advanced thermodynamic models and full GMP demonstrator trials. By combining MESOX’s expertise in nanopore carrier drug delivery with EuroAPI’s established scale-up and modeling capabilities,
MESOX, a pioneering pharmaceutical company, has been awarded the prestigious Start-Up Award at the Medilink Midlands Business Awards 2024. This recognition celebrates MESOX’s outstanding achievements in life sciences, particularly its crucial work in transforming pharmaceutical formulation through its game-changing carrier technologies. This award not only highlights MESOX’s innovative approach to drug delivery but also underscores
MESOX has been selected as a key participant in the UK government’s Reducing Drug Deaths Innovation Challenge Phase 1 SBRI programme. Its innovative RescuePatch project, a groundbreaking transdermal patch designed to combat fatal drug overdoses, has been recognized as a standout among the 11 selected projects. RescuePatch is a unique, controlled-release combination patch that delivers